Key result
A meds-to-beds program providing pharmacist counseling and free dual antiplatelet therapy did not reduce 30-day all-cause readmissions post-PCI.
Why the study?
Unplanned hospitalizations following PCI are common and costly, but health system interventions to reduce readmissions in this population are not well described.
Does a meds-to-beds program reduce 30-day all-cause hospital readmissions in adults who received PCI?
Observational (n=662)
No
Does a meds-to-beds program reduce 30-day all-cause hospital readmissions in adults who received PCI?
Answers are grounded in this paper and cite their sources.
A meds-to-beds program providing pharmacist counseling and a free 1-month supply of dual antiplatelet therapy did not significantly reduce 30-day all-cause readmissions after PCI.
BACKGROUND: Unplanned hospitalizations following percutaneous coronary intervention (PCI) are common and represent an opportunity to improve outcomes and reduce costs. However, health system interventions to reduce readmissions in this population are not well described. OBJECTIVES: We aimed to implement a meds-to-beds program and evaluate its impact on 30-day readmissions. METHODS: We performed an observational study among a medically underserved diverse cohort of adults who received emergent or elective PCI at an academic medical center in Bronx County, NY. The meds-to-beds program consisted of a pharmacist-directed counseling and a free, 1-month supply of dual antiplatelet therapy before discharge. The intervention was compared to the standard of care control group that received instructions and dual antiplatelet therapy prescriptions at discharge. The primary outcome was 30-day all-cause hospital readmissions. Secondary outcomes included 30-day cardiac-related readmissions and provider satisfaction. RESULTS: A total of 662 patients were included. In a multivariable analysis, 30-day all-cause readmissions did not differ between the intervention and control groups with respective incidences of 9.0% and 9.7% (OR: 1.07; 95% CI: 0.58-1.97). Although the 30-day cardiac-related readmission rate was significantly lower in the intervention group (2.9%) compared to the control group (6.3%), this association did not remain significant after confounder adjustment (OR: 0.50; 95% CI: 0.21-1.18). Providers perceived that the intervention improved safety and quality during transitions of care. CONCLUSIONS: A meds-to-beds program was not associated with readmission reduction among adults who received PCI. Other measures, such as medication adherence and patient satisfaction, could be employed to assess the effectiveness of future medication delivery programs.
No takes yet. Share an insight, caveat, or question.
Palo et al. (2026) conducted an observational in Percutaneous coronary intervention (PCI) (n=662). Meds-to-beds program vs. Standard of care control group was evaluated on 30-day all-cause hospital readmissions (OR 1.07, 95% CI 0.58-1.97). A meds-to-beds program providing pharmacist counseling and free dual antiplatelet therapy did not reduce 30-day all-cause readmissions post-PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: